Xencor Inc
Xencor Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on engineered antibody therapeutics. The company develops XmAb-based drug candidates and antibody engineering technologies for cancer and autoimmune diseases, and it also licenses its platforms and candidates to collaborators.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaInternally discovered XmAb antibody candidates advanced through preclinical and clinical development.
Licenses to use Xencor's XmAb and Xtend platforms in partner programs.
Milestone payments earned when partners achieve development or regulatory events.
Ongoing royalty income from marketed products developed using Xencor technology.
Tuotteet
Raportoitu · osuus liikevaihdosta- Royalty63,9 %
- Milestone36,1 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Xencor's direct customers are pharmaceutical and biotechnology partners that license its antibody engineering technologies or collaborate on drug candidates. The company also serves clinical and commercial end markets indirectly through its own pipeline and through partner-developed medicines that use XmAb technologies.
License Xencor's antibody engineering platforms and pay upfront, milestone, and royalty consideration.
Co-develop early-stage antibody programs and use Xencor's technology to accelerate discovery and clinical work.
Take over selected Xencor-originated candidates for later-stage development and potential commercialization.
The ultimate end market for Xencor's internal pipeline and partner programs, especially in unmet-need settings.
Strategia
Xencor's strategy is to use its XmAb protein engineering platform to create differentiated antibody therapeutics and then decide program-by-program whether to advance, partner, or discontinue assets. It seeks to retain economic upside through royalties, milestones, and commercial rights while using collaborators' development and commercialization capabilities where appropriate.
Clinical data determine which candidates can move toward later-stage development and potential commercialization.
Collaborations provide non-dilutive funding and external development capacity while preserving upside.
A broader technology base can generate more candidates, more partner programs, and more royalty-bearing products.
Maantiede
Xencor is headquartered in Pasadena, California and operates as a U.S.-based research and development company. Its business is global in scope because clinical trials, licensing, manufacturing, and commercialization activities can involve partners and regulators in the United States, Europe, and other foreign markets.
Riskit
Xencor depends on successful clinical development, regulatory approval, and partner execution, all of which are uncertain in biopharmaceutical development. Its revenue is concentrated in collaboration, milestone, and royalty arrangements, so timing of partner events and the performance of marketed partner products can materially affect results.
- Capital requirements and dilutionVaikutus: KorkeaTodennäköisyys: Korkea
Clinical-stage biopharma companies often need external financing before product sales are available.
Kohdistuu: Pipeline funding and operating flexibility
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Drug candidates may not show sufficient safety or efficacy to advance, which can end a program after significant R&D spend.
Kohdistuu: Internal pipeline and co-development programs
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even promising candidates require FDA and foreign approvals before trials or commercialization can proceed.
Kohdistuu: Global clinical and commercialization plans
- Partner concentration and execution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Milestones and royalties depend on third-party partners advancing programs and selling products successfully.
Kohdistuu - Intellectual property protectionVaikutus: KeskitasoTodennäköisyys: Matala
The value of XmAb technologies depends on patent and license protection against imitation or disputes.
Kohdistuu: Platform technologies and licensed candidates
Kirjanpito
Harkinnanvaraiset erätUpfront fees, milestones, and royalties must be allocated and recognized based on performance obligations and variable consideration.
Vaikutus: Can materially shift revenue between periods
Royalties from marketed partner products depend on sales reports and may be recognized as non-cash revenue.
Vaikutus: Creates recurring but partner-dependent revenue
Clinical and manufacturing services are often billed after work is performed, requiring estimates at period-end.
Vaikutus: Affects operating expense timing
Investment gains, losses, and impairments flow through other income (expense), net.
Vaikutus: Can add volatility outside core operations
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Päivitetty: 24.9.2026